Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figs Inc (FIGS) vs Mesoblast Limited (MESO) Price & Performance

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Figs Inc vs Mesoblast Limited — how do they compare? Figs Inc trades at $14.26 (market cap $2.39B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Figs Inc and Mesoblast Limited are close in size by market cap, and Figs Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

FIGSMESO
Market Cap
$2.39B$2.16B
Sector
Consumer CyclicalTechnology
52-Week High
$17.12$20.96
52-Week Low
$6.57$12.88
Enterprise Value
$2.15B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figs Inc

FIGS stock surged 26.87% to $14.26, supported by strong Q2 2026 earnings that beat estimates with $0.11 EPS and 29% revenue growth. The technical outlook is bullish with moving averages aligned positively, while fundamentals show improving profitability with a net income margin of 8.72% and robust gross margins near 69%. Recent news highlights institutional buying and raised full-year guidance, reflecting strong operational momentum.

The outlook remains positive given consistent earnings beats and upward revenue revisions, though the stock's high P/E of 43.21 suggests premium valuation risks. Key investor risks include cost pressures from tariffs and freight, alongside competitive threats in the healthcare apparel space. Analyst consensus is bullish with a $19.50 price target, indicating potential upside from current levels.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Figs Inc

FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.

Read more on FIGS

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO